Introducing one of The World’s Most Influential Scientific Minds – the inspiration behind Champignon Brands (CSE:SHRM│OTC:SHRMF)

By Richard Mason


Combining substantial short-term cash flow with blue-sky drug discovery

Combining substantial short-term cash flow with blue-sky drug discovery – read our EXCLUSIVE REPORT on how Champignon Brands (CSE:SHRMOTC:SHRMF) will conquer the market for psychedelic medicines.

Dr Roger McIntyre has been called one of the ‘World’s Most Influential Scientific Minds’.

He is a leading global expert in mood disorders, and perhaps the most published professor in the mental health field.

When Dr McIntyre speaks, the professional medical community and public at large pay serious attention.

His research is second to none.

Dr McIntyre’s enormous contribution to our understanding and management of mental health conditions is widely respected. Now, his primary focus is the use of compelling science to support the millions and millions around the world suffering from “treatment-resistant” disorders. 

More than 300 million people on this planet suffer from depression. That’s roughly 4% of the population—one in 25 of us.

Yet despite this global crisis, traditional antidepressants have a poor track record of success- effective in as few as 10-15% of cases.

Given the worldwide market for antidepressants is expected to reach $28.6 billion in 2020, this is a shocking situation.

Living with the burden of depression can leave sufferers in a desperate state.

Not only are traditional antidepressants ineffective, but they also are slow to act and can have terrible side effects.

Ineffectual treatment of depression can compound its negative consequences, pushing sufferers into a spiral of desolation.

But hope is on the horizon.

The revolutionary new field of psychedelic medicine promises to transform mental health care forever.

Dr McIntyre is at the head of this radical movement, having dedicated his career to pursuing innovative therapies for healing minds and bodies.

His approach combines careful drug administration with therapeutic rehabilitation in a specialist clinical setting.

Amazingly, Dr McIntyre’s specially-designed treatment methods are seeing success rates of 40-60%!

One of the leading champions of “rapid onset treatments”, Dr McIntyre is now primed for full-scale expansion across North America and has embarked on his most ambitious project yet.

He has become chief executive of Champignon Brands (CSE:SHRMOTC:SHRMF).

Download our EXCLUSIVE REPORT to learn how Champignon Brands (CSE:SHRMOTC:SHRMF) has seized first-mover advantage in the psychedelic medicines space

Champignon Brands (CSE:SHRMOTC:SHRMF) is an exciting new healthcare company that combines blue-sky drug development with substantial short-term revenue potential.

The firm is at the cutting-edge of psychedelic medicine; discovering innovative and effective treatments for a range of mental health conditions ranging from anxiety and post-traumatic stress disorder to depression.

Research into psychedelic medicines has come to the fore in recent years since being granted “breakthrough status” by both the U.S. Food and Drug Administration and Canada Health. This means the approval process for such treatments has been fast-tracked.

Gaining the support of two highly influential health regulators was an enormous milestone for psychedelic medicine.

Dr McIntyre and his team were already pursuing ground-breaking research into psychedelic medicines could after recognizing how valuable they could be in providing successful long-term care for mental health sufferers.

As the wider academic and research community woke up to this new phenomenon, the results of the testing were so impressive they could not be kept from the public any longer.

Psychedelic medicines were fast emerging as THE preferred and most positive treatments for mood disorders.

The relaxation of previously strict regulations enabled more significant studies examining the health benefits of psychotherapeutic treatments to be undertaken.

Tens of millions of dollars flowed into respected research institutions, from John Hopkins University and Yale to the University of Miami and the University of Wisconsin.

However, these foundations were all playing catch-up.

Dr McIntyre and his team were already way out in front, and Champignon Brands (CSE:SHRMOTC:SHRMF) is now leading the charge into this brave new world of effective mental health care. 

Dr McIntyre’s head-start allowed him and his team to quickly start formulating and manufacturing novel psychedelic medicines with incredible potential.

Today, this translates into an exceptional competitive advantage for Champignon Brands (CSE:SHRMOTC:SHRMF).

Unlike other drug discovery companies, Champignon Brands (CSE:SHRMOTC:SHRMF) is on course to start generating substantial revenues by year-end.

With the medical effectiveness and money-making potential of his treatment methods confirmed, Dr McIntyre is ready to expand his reach to a much larger patient population.

SPECIAL REPORT DOWNLOAD – Discover how Champignon Brands’ (CSE:SHRMOTC:SHRMF) clinics will reach a patient population of 80 million within months

Two years ago, Dr McIntyre founded the first of his comprehensive research and treatment centres; the Canadian Rapid Treatment Centre of Excellence in Toronto (the “CRTCE”).

Here, Dr McIntyre brought his lifetime of experience into a place where it could help patients the most. His clinic was the first to be licensed by Health Canada to administer psychedelic medicines to eligible patients under randomized controlled trials.

In March, Champignon Brands (CSE:SHRMOTC:SHRMF) bought AltMed, which owns 100% of the CRTCE.

In its first full year of operation, the CRTCE administered more than 1,500 psychedelic medicinal treatments to more than 300 patients. This generated revenue in excess of $1 million and, much more importantly, saw success rates as high as 60% in patients.

This is truly a game-changer for patients with many of the common mental health disorders, especially those with treatment–resistant depression.

The CRTCE’s standout success in deploying rapid onset treatments is a phenomenal achievement nor being recognized by leading medical research institutions.

Champignon Brands’ (CSE:SHRMOTC:SHRMF) plan is now to roll out this lucrative model across the United States.

The company plans to open five new specialist treatment clinics by Q4 2020.

New York, Florida and California will be ready for business within months, supporting an 80-million-people-strong  catchment area.

Given the stunning 60% success rate delivered byDr McIntyre at the CRTCE, ultra-high demand is expected for places in these centres.

So much so, in fact, that Champignon Brands (CSE:SHRMOTC:SHRMF) just raised $10 million to fund its swift expansion.

Very quickly, these clinics could be generating combined revenues in excess of $10 million a year, with gross margins of 15-20%. The company has already secured its first site on the West Coast, with the acquisition of the Wellness Clinic of Orange County.

For Champignon Brands (CSE:SHRMOTC:SHRMF), this will be the front-end of a much more elaborate R&D operation. The firm’s clinics will enable direct administration of the psychedelic medicines created in its labs. In turn, data gathered from treatments will mould future drug development.

With this “virtuous circle” of research, Champignon Brands (CSE:SHRMOTC:SHRMF) has laid out a comprehensive mental healthcare pathway that can benefit millions of people in a relatively short  period.

Not only is this a massive commercial opportunity, but the positive impact it could have on society should be immense.

With its clinics set to generate ample free cash flow, helping to fund its research programs and drug discovery pipeline, Champignon Brands (CSE:SHRMOTC:SHRMF) could be an incredibly profitable addition to your stock portfolio. 


Paid Advertisement

This communication is a paid advertisement. ValueTheMarkets is a trading name of Digitonic Ltd, and its owners, directors, officers, employees, affiliates, agents and assigns (collectively the “Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Champignon Brands Inc to conduct investor awareness advertising and marketing and has paid the Publisher the equivalent of one hundred and sixty-six thousand US dollars to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher’s ability to provide unbiased information or opinion.

Changes in Share Trading and Price

Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur.

No Offer to Sell or Buy Securities

This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security.


Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position.

This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy.

No Financial Advice

The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual’s financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results.

Forward Looking Statements

This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company’s actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company’s operations; the size and growth of the market for the company’s products and services; the company’s ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company’s business.

Indemnification/Release of Liability

By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions.

Terms of Use and Disclaimer

By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here and acknowledge that you have reviewed the Disclaimer found here If you do not agree to the Terms of Use, please contact to discontinue receiving future communications.

Intellectual Property

All trademarks used in this communication are the property of their respective trademark holders. Other than, the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than

Authors: Ben Turney and Daniel Flynn and Digitonic Ltd and our affiliates are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above.

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance.

Ben Turney and Daniel Flynn do not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. Ben Turney and Daniel Flynn have been paid to produce this piece by the company or companies mentioned above. Digitonic Ltd, the owner of, has been paid for the production this piece by the company or companies mentioned above.


In this article:

Author: Richard Mason

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Digitonic Ltd, the owner of, does not hold a position or positions in the stock(s) and/or financial instrument(s) mentioned in the above article.

Digitonic Ltd, the owner of, has not been paid for the production of this piece by the company or companies mentioned above.

Sign up for Investing Intel Newsletter